- General Drug Summary
- Description
- Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. [PubChem]
- Also Known As
- Amdinocillin pivoxil; Pivmecilinamo [inn-spanish]; Pivmecillinamum [inn-latin]
- Categories
- Anti-Infective Agent
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for Pivmecillinam Effective in Inducing Remission in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 23344280
- Pivmecillinam
- Effective in Inducing Remission
- Clinical Trial
- Summary
- Act as a disase comparison group to test the outcomes exposure to nitrofurantoin.
- Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and gynecology, 2013 Feb [Go to PubMed]
- To estimate whether first-trimester exposure to nitrofurantoin is associated with increased malformation rates and, secondarily, to estimate whether exposure to nitrofurantoin is associated with increased rates of negative pregnancy outcomes and perinatal complications.
We conducted a population-based cohort study using the Norwegian Prescription Database linked to data on all live births, stillbirths, and induced abortions after 12 weeks of gestation from The Medical Birth Registry of Norway. The study population consisted of 180,120 pregnancies in 2004-2008. The pregnancy outcomes of women who were dispensed nitrofurantoin during pregnancy were compared with the outcomes of women who were dispensed pivmecillinam (disase comparison group) and unexposed women.
In all, 5,794 (3.2%) filled prescriptions for nitrofurantoin during pregnancy, 1,334 women (0.7%) in the first trimester and 979 women (0.5%) in the last 4 weeks of pregnancy. Dispensing nitrofurantoin during the first trimester was not associated with increased risk of major malformations (31 of 1,334 [2.3%]) compared with disease controls (162 of 5,800 [2.8%], odds ratio [OR] 0.79, 95% confidence interval [CI] 0.51-1.23). No increased risk for secondary adverse pregnancy outcomes was observed when compared with the disease comparison group. Dispensing nitrofurantoin the last 30 days before delivery was associated with increased risk of neonatal jaundice (103 of 959 [10.8%]) compared with unexposed women (10,336 of 127,507 [8.1%], OR 1.31, 95% CI 1.02-1.70).
The results from this large, population-based study suggest that the teratogenic potential of nitrofurantoin is low.
II.